2 results
Approved WMOCompleted
Primary: To determine whether ofatumumab 3, 30 or 60 milligrams (mg) given subcutaneously (SQ), reduces the cumulative number of new T1 GdE brain lesions over a period of 12 weeks, as compared with placebo.Secondary: Cumulative number of new T1 GdE…
Approved WMOCompleted
The primary aim is to investigate whether six weeks augmentation with clonidine of the antipsychotic treatment will reduce positive and negative symptomatology of treatment resistant schizophrenia patients. Important secondary goals of this project…